Advanced Prostate Cancer May be Cured By Immunotherapy, Trial Reveals

Mateus Crespo/Professor Johann de Bono/The Institute of Cancer Research A new major clinical  study  has revealed positive outcomes in ...

A new major clinical study has revealed positive outcomes in the use of immunotherapy in the treatment of otherwise untreatable prostate cancer. The study is the first trial to reveal such results with this type of cancer giving hope to patients running out of options.
The international trial, led by The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust, featured 258 subjects with advanced prostate cancer put under treatment of pembrolizumab, a humanized antibody with the brand name Keytruda. After a year, 38% of the subjects were still alive and 11% showed impressive remissions as well as prolonged disease control.

DNA repair mutations

“In the last few years immunotherapy has changed the way we treat many advanced cancers – but up to now, no one had demonstrated a benefit in men with prostate cancer. Our study has found that immunotherapy can benefit a subset of men with advanced, otherwise untreatable prostate cancer, and these are most likely to include patients who have specific DNA repair mutations within their tumours,” said Professor Johann de Bono, Director of the Drug Development Unit at the ICR, and at The Royal Marsden NHS Foundation Trust.
The team is now working on a new immunotherapy trial targeting prostate cancer patients with tumors exhibiting those mutations. One of immunotherapy’s major challenges is that there are currently no reliable tests to determine who can benefit from the treatment.
The current trial indicates that the presence of mutations in DNA repair genes may be a valuable marker of those likely to respond well. The study is a comparative analysis of the effectiveness of pembrolizumab in subjects with tumors presenting PD-L1 proteins on their surface and subjects without the protein.

PD-L2 a potential better marker

The study revealed that PD-L1 testing, unfortunately, was not sufficient to tell which patients would respond adequately to pembrolizumab but produced some evidence that testing for the PD-L2 protein could provide a better marker. If the new trial should produce similar results, it would provide hope for patients running out of options.
“Immunotherapy has proven to be a smarter, kinder treatment for many types of cancer – but it still only works for a minority of patients. The challenges we now face are how to predict in advance who will benefit, and how to make immunotherapy work for more people,” said professor Paul Workman, Chief Executive of the ICR.
So far the trial has brought a happy ending to at least a few of its subjects. Michael English, a 72-year-old patient who was treated with pembrolizumab in 2016, said he had tried many options before with no outcome. 
“I was diagnosed with prostate cancer in 2005, and over a number of years I had hormone therapies, radiotherapy and chemotherapy, including treatment in research trials. Professor de Bono recommended pembrolizumab based on a genetic test and after only a few three-weekly cycles, we were astonished when scans showed that the tumour had become undetectable," said English.



Agriculture,4,Architecture,5,Automobiles,35,Biography,1,Computers,8,Cryptocurrency,1,Driverless,6,Electric Cars,3,Energy,8,Engineering,2,Environment,4,Flying Cars,2,Gadgets,10,Health Science,18,Internet,6,Language,1,Mobile Phones,18,Nuclear,5,Safety,1,Science,5,Solar,7,Space Science,23,Technology News,38,Warfare,6,
Lifi Digital - Latest Tech News from around the globe: Advanced Prostate Cancer May be Cured By Immunotherapy, Trial Reveals
Advanced Prostate Cancer May be Cured By Immunotherapy, Trial Reveals
Lifi Digital - Latest Tech News from around the globe
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS CONTENT IS PREMIUM Please share to unlock Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy